Description
In this presentation led by Robert Ashford, the focus is on the significant issue of metastatic disease, particularly in bone metastases. Ashford introduces the topic by emphasizing the universal occurrence of bone metastases across different types of primary cancers, noting the stark variance in incidence rates—ranging from nearly 100% in multiple myeloma to 0% in uterine cancer. He examines survival rates related to various cancers, illustrating how while incidence rates are on the rise, mortality rates are decreasing, largely attributed to advancements in oncology rather than orthopedic surgeries.
He highlights the necessity of accurate survival predictions for patients with metastatic disease, suggesting tools like OPTIModel and PATHFx to aid in prognosis estimation. Ashford outlines the startling statistic that 27% of breast cancer survivors develop bone metastases, translating to approximately 15,000 cases annually, a problem that is expected to worsen in the future. Through data from audits and reviews among various institutions, he discusses the typical management strategies for these cases, underscoring the variability in treatment approaches for metastatic diseases.
The presentation addresses the twofold issue of increasing patient survival and the number of patients living with metastatic diseases, advising that comprehensive assessments and appropriate oncological consultations are vital in managing such cases effectively. Ashford emphasizes the importance of careful consideration before any surgical intervention to avoid unnecessary procedures and complications, particularly in complex patient scenarios. Overall, the talk outlines the evolving landscape of metastatic disease management, the importance of technology in prognosis, and the critical role of oncologists in treatment planning.